| # | Drug | Count |
|---|---|---|
| 0 | CAPECITABINE | 6732 |
| 1 | CABOZANTINIB | 3165 |
| 2 | SORAFENIB | 2174 |
| 3 | BEVACIZUMAB | 1633 |
| 4 | SUNITINIB MALATE | 1455 |
| 5 | REGORAFENIB | 1446 |
| 6 | OXALIPLATIN | 1423 |
| 7 | TRASTUZUMAB | 1325 |
| 8 | PEMBROLIZUMAB | 1197 |
| 9 | LENVATINIB | 1028 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | REGORAFENIB | 1446 | 0.1245 |
| 1 | SORAFENIB | 2174 | 0.1050 |
| 2 | CAPECITABINE | 6732 | 0.0731 |
| 3 | CABOZANTINIB | 3165 | 0.0656 |
| 4 | LAPATINIB | 931 | 0.0603 |
| 5 | UREA | 85 | 0.0384 |
| 6 | SUNITINIB MALATE | 1455 | 0.0372 |
| 7 | RIPRETINIB | 189 | 0.0360 |
| 8 | VINORELBINE | 243 | 0.0349 |
| 9 | FRUQUINTINIB | 133 | 0.0337 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 7564 |
| 1 | Kinase Inhibitor [EPC] | 3539 |
| 2 | Platinum-based Drug [EPC] | 2147 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1685 |
| 4 | Microtubule Inhibitor [EPC] | 1612 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 1353 |
| 6 | Corticosteroid [EPC] | 1194 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1082 |
| 8 | Alkylating Drug [EPC] | 814 |
| 9 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 767 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 7564 | 0.0276 |
| 1 | HER2/neu Receptor Antagonist [EPC] | 1353 | 0.0181 |
| 2 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 17 | 0.0111 |
| 3 | Epidermal Growth Factor Receptor Antagonist [EPC] | 526 | 0.0111 |
| 4 | Microtubule Inhibitor [EPC] | 1612 | 0.0097 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1685 | 0.0091 |
| 6 | Platinum-based Drug [EPC] | 2147 | 0.0078 |
| 7 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 767 | 0.0078 |
| 8 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 45 | 0.0071 |
| 9 | Kinase Inhibitor [EPC] | 3539 | 0.0063 |